<DOC>
	<DOCNO>NCT02771249</DOCNO>
	<brief_summary>People human immunodeficiency virus ( HIV ) often take several medicine control HIV . Dolutegravir darunavir boost cobicistat HIV medicine people may take . They may also need take medicine infection call latent tuberculosis ( TB ) . Researchers think once-weekly treatment latent TB would easier people HIV take . This weekly treatment consist two drug : rifapentine isoniazid . However , need see TB drug HIV drug interact . Objective : To learn anti-HIV anti-TB drug affect people take drug together treat safely . Eligibility : Healthy adult age 18 65 . Design : Participants screen medical history physical exam . They vital sign take give blood sample . Women pregnancy test . Participants take medicine study , include vitamin . Only occasional , infrequent use acetaminophen ( Tylenol , max 2000 mg/day ) , ibuprofen ( Motrin Advil ) , naproxen ( Aleve ) , loperamide ( Imodium ) , and/or antihistamine ( Benadryl , Zyrtec , Claritin , etc . ) allow . Participants assign one three group . Each group take different study drug , twice day , 19 23 day . At baseline study visit , get supply study drug tablet instruction take . Participants keep medicine diary serve memory aid take medicine report side effect may experience . Participants 8 9 study visit 40 day . The number visit depends group person assign . All visit take place NIH Clinical Center . Participants fast study visit . The baseline visit last 2 3 hour . There 3-4 long visit last 12 hour . The 4-5 visit last 1 hour . During study visit , screen procedure repeat . During long visit , intravenous ( IV ) line insert arm vein needle . It use take blood .</brief_summary>
	<brief_title>Impact Once-Weekly Rifapentine Isoniazid Steady State Pharmacokinetics Dolutegravir Darunavir Boosted With Cobicistat Healthy Volunteers</brief_title>
	<detailed_description>Rifapentine ( RPT ) long-acting rifamycin use weekly isoniazid ( INH ) first-line regimen treatment latent tuberculosis infection ( LTBI ) . Although regimen offer several potential benefit , use weekly RPT plus INH currently recommend adult infected human immunodeficiency virus ( HIV ) antiretroviral therapy ( ART ) due limited evidence drug interaction antiretrovirals ( ARVs ) . Dolutegravir ( DTG ) darunavir boost cobicistat ( DRV/c ) comprise part first-line alternative treatment regimen , respectively , recommend treatment HIV . However , drug interaction ARV agent RPT concern . Thus , purpose study determine effect concomitant RPT INH administration steady state PK DTG DRV/c . This open-label , fixed sequence , intrasubject drug-drug interaction study design evaluate steady state PK DTG DRV/c coadministration weekly RPT INH give dos use treat LTBI . Up three study arm examine : DTG daily ( Arm A ) , DRV/c daily ( Arm B ) , DTG twice daily ( Arm C ) . Arm B begin recruitment follow completion Arm A . Arm C conduct Arm A result reveals may necessary . Arms A B comprise two phase : ( 1 ) DTG DRV/c daily alone ( day 1-4 ) ( 2 ) DTG DRV/c daily + ( RPT INH ) weekly ( day 5-19 ) . Arm C comprise three phase : ( 1 ) DTG daily alone ( day 1-4 ) , ( 2 ) DTG twice daily alone ( day 5-8 ) , ( 3 ) DTG twice daily + ( RPT INH ) weekly ( day 9-23 ) . Participants Arms A B undergo periodic serial ARV PK blood draw day 4 , 14 , 19 , single trough draw Day 17 18 . Arm C participant PK blood draw day 4 , 8 , 18 , 23 , single trough draw Day 21 22 . DTG DRV/c PK parameter determine use non-compartmental method . Cobicistat level assess DRV concentration significantly decrease Arm B . The following PK parameter compare phase : area curve dose interval , maximum plasma concentration , time maximum plasma concentration , terminal half-life , apparent oral clearance , minimum plasma concentration . Adverse event grade record .</detailed_description>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>INCLUSION CRITERIA : A subject consider eligible study follow criterion meet : 1 . Ages 18 65 year 2 . Weight great equal 45 kg less equal 120 ; BMI great equal 18.0 &lt; 30 3 . Judged healthy base medical history , physical examination , vital sign , clinical laboratory test ( liver function test ( AST , ALT , Tbili ) great equal upper limit normal [ ULN ] , serum creatinine ( SCr ) less equal ULN , CK le equal 2X ULN , lipase less equal ULN , platelet ( PLT ) &gt; 150,0000/mm3 , hemoglobin ( Hgb ) &gt; 11 g/dL ) 4 . Negative QuantiFERONTB Gold test screen 5 . HIVnegative , determine standard serologic assay HIV infection . 6 . No laboratory evidence active Hepatitis A , B , C infection 7 . Willing abstain alcohol consumption throughout study period 8 . Subject agree genetic test storage specimens future research 9 . Negative serum urine pregnancy test female childbearing potential 10 . For female subject able become pregnant ( i.e. , undergone surgical sterilization postmenopausal ) , willingness prevent pregnancy study period : 1 . Practicing absolute abstinence sexual contact 2 . Committing use effective nonhormonal and/or barrier method birth control sexual encounter . Acceptable method follow : Condom , diaphragm , cervical cap spermicide Intrauterine device ( IUD ) without hormone Male partner vasectomy EXCLUSION CRITERIA : A subject ineligible study 1 , , follow criterion meet : 1 . Known hypersensitivity dolutegravir , darunavir , cobicistat , rifapentine rifamycin analogue , isoniazid 2 . History type 1 hypersensitivity reaction sulfonamides 3 . History presence following : 1 . Latent active TB infection 2 . Gastrointestinal disease uncontrolled , require daily treatment medication , would interfere subject ability absorb drug ( diarrhea , pancreatitis , peptic ulcer disease , etc . ) , 3 . Renal impairment ( chronic renal insufficiency CKD stage , acute renal failure induce drug therapy define GFR &lt; 90 ml/min ) 4 . Respiratory disease uncontrolled require daily treatment medication ( asthma , chronic obstructive pulmonary disease , etc . ) 5 . Cardiovascular disease ( hypertension [ systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg ] , heart failure , arrhythmia , etc . ) 6 . Metabolic disorder ( diabetes mellitus , etc . ) 7 . Hematologic bleed disorder ( anemia , hemophilia , serious/major bleed event , menorrhagia ( female subject ) , etc . ) 8 . Immunologic disorder 9 . Hormonal endocrine disorder 10 . Psychiatric illness would interfere ability comply study procedure require daily treatment medication 11 . Seizure disorder , exception childhood febrile seizures 12 . Malignancy , 13 . Any condition may interfere interpretation study result , best interest subject opinion investigator 4 . Fasting total cholesterol &gt; 240 mg/dL fast triglyceride &gt; 240 mg/dL 2 consecutive visit 5 . Fasting glucose &gt; 125 mg/dL 2 consecutive visit 6 . Current participation onging investigational drug protocol use investigational drug within 30 day ( base last dose receive ) prior receipt study drugs/medications . 7 . Therapy prescription , overthecounter , herbal , holistic medication , include hormonal contraceptive route , within 5 halflives agent prior receipt study medication permit follow exception : Intermittent shortcourse therapy ( &lt; 14 day ) prescription overthecounter medication , herbal , holistic medication within screen period prior start study drug may permit , review investigator casebycase basis potential drug interaction . Receipt influenza vaccination allow prior , , and/or study 8 . Inability obtain venous access sample collection 9 . Inability swallow whole capsule and/or tablet 10 . Current breastfeed 11 . Drug alcohol use may impair safety adherence 12 . Use nicotinecontaining product , include cigarette chew tobacco , nicotine patch , gum , electronic cigarette , etc . 13 . Organ stem cell transplant recipient 14 . Uncorrected persistent electrolyte abnormality ( e.g. , potassium , magnesium , calcium ) 15 . Current alcohol abuse alcohol dependence disorder ( DSM5 criterion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 20, 2017</verification_date>
	<keyword>Latent Tuberculosis Infection ( LTBI )</keyword>
	<keyword>Antiretrovirals ( ARVs )</keyword>
	<keyword>HIV</keyword>
	<keyword>UGT1A1</keyword>
	<keyword>Drug-Drug Interaction ( DDI )</keyword>
</DOC>